ReviewCells2021
Role of Gonadotropin-Releasing Hormone (GnRH) in Ovarian Cancer.
Review in Cells, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 1 synthesis or guideline pooled it, 53 citations in OpenAlex.
- Association between ovarian tumors and exposure to assisted reproductive technologies and ovarian stimulation: a systematic review and meta-analysis.Archives of gynecology and obstetrics · 2024Pooled it
- NMR Structural Elucidation of Mitoxantrone-Gonadotropin-Releasing Hormone (GnRH) Conjugates Implicated in Hormone-Dependent Cancer.International journal of molecular sciences · 2026Article
- Oxidative Stress-Related KEAP1 and NRF2 Genes Contributed to the Risk of Epithelial Ovarian Cancer.Biochemical genetics · 2026Article
- Luteinizing Hormone-Releasing Hormone (LHRH)-Targeted Treatment in Ovarian Cancer.International journal of molecular sciences · 2025Review
- Hybrid Dihydropyrimidinones Targeting AKT Signaling: Antitumor Activity in Hormone-Dependent 2D and 3D Cancer Models.Pharmaceutics · 2025Article
- Radiolabeled LHRH and FSH Analogues as Cancer Theranostic Agents: A Systematic Review.Journal of clinical medicine · 2025Review
- Disruption of ovarian function and induction of apoptosis in female mice by Brefeldin A: Mechanistic insights into reproductive toxicity.Animal models and experimental medicine · 2025Article
- Therapeutic Insights intoPharmaceuticals (Basel, Switzerland) · 2025Article
- A Near-Infrared Fluorescent Probe for Specific Imaging of Lymph Node Metastases in Ovarian Cancer via Active Targeting of the Gonadotropin-Releasing Hormone Receptor.Biomolecules · 2025Article
- GnRH Peptide Antagonist: Comparative Analysis of Chemistry and Formulation with Implications for Clinical Safety and Efficacy.Pharmaceuticals (Basel, Switzerland) · 2024Review
- Cytotoxic Activity of Novel GnRH Analogs Conjugated with Mitoxantrone in Ovarian Cancer Cells.Molecules (Basel, Switzerland) · 2024Article
- Targeted lipidomics analysis of possible molecular mechanisms of lipid changes in temporal lobe epilepsy models.Frontiers in pharmacology · 2024Article
- New insights for gynecological cancer therapies: from molecular mechanisms and clinical evidence to future directions.Cancer metastasis reviews · 2023Review
- Crosstalk between ferroptosis and steroid hormone signaling in gynecologic cancers.Frontiers in molecular biosciences · 2023Review
- Peptides for diagnosis and treatment of ovarian cancer.Frontiers in oncology · 2023Review
- Prognostic value of β-Arrestins in combination with glucocorticoid receptor in epithelial ovarian cancer.Frontiers in oncology · 2023Article
- Article
- Learn from antibody-drug conjugates: consideration in the future construction of peptide-drug conjugates for cancer therapy.Experimental hematology & oncology · 2022Review
- Analysis of Prediagnostic Circulating Levels of Gonadotropins and Androgens with Risk of Epithelial Ovarian Cancer.Journal of laboratory physicians · 2022Article
- Effects of Luteinizing Hormone Releasing Hormone A2 on Gonad Development in Juvenile Amur Sturgeon, Acipenser schrenckii, Revealed by Transcriptome Profiling Analysis.Frontiers in genetics · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The hypothalamus-pituitary-gonadal (HPG) axis is the endocrine regulation system that controls the woman's cycle. The gonadotropin-releasing hormone (GnRH) plays the central role. In addition to the gonadotrophic cells of the pituitary, GnRH receptors are expressed in other reproductive organs, such as the ovary and in tumors originating from the ovary. In ovarian cancer, GnRH is involved in the regulation of proliferation and metastasis. The effects on ovarian tumors can be indirect or direct. GnRH acts indirectly via the HPG axis and directly via GnRH receptors on the surface of ovarian cancer cells. In this systematic review, we will give an overview of the role of GnRH in ovarian cancer development, progression and therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.